Osteoporosis Treatment in India & UAE — Expert Bone Density & Fracture Care
Osteoporosis treatment in India from $500. Bisphosphonates, denosumab, teriparatide & fracture surgery by metabolic bone disease specialists. Book with GAF Healthcare.
Estimated cost: $500 – $3,000 · Average stay: 1–5 days
Osteoporosis is a systemic skeletal disease characterised by reduced bone mineral density (BMD) and deterioration of bone microarchitecture, leading to increased fragility and susceptibility to fractures. It affects an estimated 200 million women worldwide and a significant proportion of men over 70. Osteoporotic fractures — particularly of the hip, vertebral bodies, and distal forearm — are among the leading causes of morbidity, disability, and mortality in older adults. A hip fracture in an older patient carries a 20–30% risk of death within one year.
India and the UAE have specialist metabolic bone disease clinics and endocrinologists with expertise in the complete assessment, prevention, and treatment of osteoporosis — including DEXA bone density scanning, vertebral fracture assessment, fracture risk calculation (FRAX tool), prescription of the full range of modern anti-osteoporosis medications, and surgical management of fragility fractures.
For international patients who have been diagnosed with osteoporosis or who have suffered a fragility fracture, India offers comprehensive expert assessment and treatment initiation at costs far below equivalent specialist care in the UK, USA, or Australia.
Understanding Osteoporosis and Fracture Risk
Osteoporosis is defined by the World Health Organisation as a bone mineral density T-score of −2.5 or below on DEXA scanning (comparing the patient's BMD to the mean BMD of a healthy young adult reference population). Osteopenia — reduced bone density that has not yet reached the osteoporotic threshold — is defined as a T-score between −1.0 and −2.5.
The FRAX tool (WHO Fracture Risk Assessment Tool) calculates the 10-year probability of major osteoporotic fracture (hip, vertebral, forearm, or humerus) based on age, BMD, and clinical risk factors including: prior fragility fracture, family history of hip fracture, current smoking, alcohol intake, long-term corticosteroid use, rheumatoid arthritis, and secondary causes of bone loss. The FRAX score guides treatment decisions — pharmacological treatment is recommended when the 10-year fracture probability exceeds country-specific thresholds.
Secondary osteoporosis (from a specific underlying cause) must be excluded before primary osteoporosis treatment is initiated: common causes include hyperparathyroidism, vitamin D deficiency, malabsorption (coeliac disease, gastric surgery), hyperthyroidism, hypogonadism, hypercortisolism (Cushing's syndrome), multiple myeloma, and medications (long-term corticosteroids, proton pump inhibitors, anticoagulants, anti-epileptics, aromatase inhibitors). A structured secondary osteoporosis screen (blood tests including calcium, PTH, 25-OH vitamin D, serum protein electrophoresis, thyroid function, sex hormones) is performed at the time of diagnosis.
Osteoporosis Treatment Approaches
All osteoporosis management begins with lifestyle measures and calcium and vitamin D supplementation, which are the foundation of bone health: adequate calcium intake (1,000–1,200 mg daily from diet and supplements); vitamin D3 supplementation to achieve serum 25-OH vitamin D above 75 nmol/L; weight-bearing exercise (walking, dancing, strength training — which stimulates bone remodelling); smoking cessation; alcohol reduction; and fall prevention (home hazard assessment, balance training, vision correction, appropriate footwear).
Bisphosphonates (alendronate, risedronate, zoledronic acid, ibandronate) are the most widely used first-line anti-osteoporosis medications. They work by inhibiting osteoclast-mediated bone resorption, increasing BMD by 3–8% at the spine and 2–5% at the hip over 3 years, and reducing vertebral fracture risk by 40–65% and hip fracture risk by 30–40%. Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) are inexpensive and highly effective. Intravenous zoledronic acid (5 mg annually) is used for patients who cannot tolerate oral bisphosphonates or who need the certainty of annual hospital administration.
Denosumab (Prolia, 60 mg subcutaneous injection every 6 months) is a RANK-L inhibitor — it blocks the signal that activates osteoclasts. It reduces vertebral fracture risk by 68% and hip fracture risk by 40%. It is preferred in patients with renal impairment (bisphosphonates are contraindicated in severe renal failure), in those intolerant of bisphosphonates, and in post-menopausal women with very high fracture risk. Importantly, denosumab must not be stopped abruptly — discontinuation causes a rebound increase in bone turnover and multiple vertebral fractures; the drug must be transitioned to a bisphosphonate on cessation.
Teriparatide (Forteo, daily subcutaneous injection) and abaloparatide are anabolic agents — they work by stimulating bone formation (unlike the anti-resorptive agents above). They produce the largest BMD gains (10–14% spine in 18 months) and are reserved for patients with the most severe osteoporosis, multiple vertebral fractures, or who have failed anti-resorptive therapy. They are expensive and time-limited (18–24 months of treatment maximum). Romosozumab (Evenity) is a newer dual-action agent that combines anti-resorptive and anabolic effects.
Surgical management of fragility fractures includes: vertebroplasty/kyphoplasty for painful vertebral compression fractures; hip fracture surgery (dynamic hip screw, intramedullary nail, or hemiarthroplasty depending on fracture pattern and activity level); and distal radius fixation for wrist fractures.
Procedure Steps
- DEXA scan (spine L1–L4 and hip); FRAX score calculation; secondary osteoporosis blood screen
- Vitamin D and calcium assessment; dietary and lifestyle counselling
- Falls risk assessment and physiotherapy for balance and strength training
- Pharmacological treatment selected and initiated based on FRAX score, BMD, and fracture history
- Annual DEXA monitoring; drug therapy reviewed at 3–5 years (bisphosphonate holiday consideration)
- Fracture liaison service referral and secondary fracture prevention programme
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $2,000 – $8,000 (specialist + tests) — Save up to 80%
UK — £800 – £3,000 (private) — Save up to 70%
UAE — $1,500 – $6,000 — Save up to 65%
India — $500 – $3,000 — Best value
A complete osteoporosis assessment in India — including DEXA scan, secondary screen blood tests, consultant review, and treatment initiation — costs $500–$1,500. Annual intravenous zoledronic acid in the USA costs $1,500–$3,000 for the medication alone; in India, the same medication costs $300–$600 administered in a day hospital setting. Denosumab injections in India cost $150–$300 per injection (every 6 months) versus $1,200–$1,500 in the USA.
Recovery & Follow-up
Medical osteoporosis treatment does not have a "recovery" in the surgical sense — patients begin medication and monitor response with annual DEXA. Surgical fragility fracture management follows the recovery protocols for the specific procedure (vertebroplasty, hip fixation) detailed on separate pages. The overarching goal is to prevent the next fracture — which is why the fracture liaison service (FLS) model — proactively identifying and treating all patients who present with a fragility fracture — is so important.
Recovery Tips
- Take your medication exactly as directed — alendronate must be taken on an empty stomach with a full glass of water, remaining upright for 30 minutes to prevent oesophageal irritation
- Take vitamin D and calcium supplements daily — they are the foundation on which all medications work
- Exercise at least 30 minutes of weight-bearing activity daily — walking, dancing, or strength training
- Remove trip hazards from the home — falls cause fractures regardless of BMD treatment
- Never stop denosumab without transitioning to a bisphosphonate — rebound vertebral fractures are a serious complication of abrupt denosumab discontinuation
Risks & Complications
Bisphosphonate risks include: oesophageal irritation (oral bisphosphonates — minimised with correct administration technique); flu-like reaction after IV zoledronic acid (first infusion — manageable with paracetamol); osteonecrosis of the jaw (ONJ — rare, primarily associated with high-dose IV bisphosphonates for cancer treatment; risk at osteoporosis treatment doses is very low — approximately 1 in 100,000 patient-years); and atypical femoral fracture (rare — fatigue fracture of the femur shaft from suppression of normal bone remodelling; risk increases with very long duration of treatment, which is why bisphosphonate holidays are recommended after 5 years). Denosumab risks include: hypocalcaemia (requires adequate calcium and vitamin D supplementation); rebound fractures on discontinuation.
Why GAF Healthcare
GAF Healthcare connects patients with India's endocrinology and metabolic bone disease specialists who provide comprehensive osteoporosis assessment and treatment initiation. For international patients who need annual zoledronic acid infusions but cannot afford or access them at home, an annual visit to India for the infusion — combined with DEXA monitoring — is a cost-effective and medically excellent approach. We provide detailed treatment plans and prescriptions in English for patients to continue their care at home.
Frequently Asked Questions
When should I start treatment for osteoporosis?
Treatment is recommended when: the FRAX 10-year fracture probability exceeds the country-specific treatment threshold; when a previous fragility fracture has occurred (secondary prevention, regardless of DEXA result); or when the DEXA T-score is below −2.5 with clinical risk factors. In some high-risk cases (previous hip fracture, multiple vertebral fractures, high-dose corticosteroid use), treatment may be initiated even with T-scores above −2.5. A specialist review is the most reliable way to determine your individual treatment need.
How long do I need to take bisphosphonates?
For most patients, oral bisphosphonates (alendronate, risedronate) are reviewed at 5 years and a 'drug holiday' (stopping the medication for 1–2 years) is considered if the fracture risk has improved. Bisphosphonate molecules accumulate in bone and continue to provide protection for 2–5 years after stopping. High-risk patients (prior hip fracture, T-score below −2.5 at the hip) are typically continued for 10 years before a holiday is considered. IV zoledronic acid is typically reviewed at 3 injections (3 years).
Can osteoporosis be reversed with treatment?
Osteoporosis treatment significantly improves bone mineral density and dramatically reduces fracture risk — but it does not fully 'reverse' established osteoporosis to normal bone in most patients. Anti-resorptive agents (bisphosphonates, denosumab) increase BMD by 3–8% at the spine; anabolic agents (teriparatide, romosozumab) increase BMD by 10–14% at the spine. The bone density improvement translates directly into fracture risk reduction. With consistent treatment, many patients return from the osteoporotic range to the osteopenic range, representing a clinically significant reduction in fracture risk.